Patterns of bone mineral density testing
Current guidelines, testing rates, and interventions
Cite this article as: Morris, C.A., Cabral, D., Cheng, H. et al. J GEN INTERN MED (2004) 19: 783. doi:10.1111/j.1525-1497.2004.30240.x Abstract OBJECTIVES: To identify potential obstacles to bone mineral density (BMD) testing, we performed a structured review of current osteoporosis screening guidelines, studies of BMD testing patterns, and interventions to increase BMD testing. DESIGN: We searched medline and HealthSTAR from 1992 through 2002 using appropriate search terms. Two authors examined all retrieved articles, and relevant studies were reviewed with a structured data abstraction form. MEASUREMENTS AND MAIN RESULTS: A total of 235 articles were identified, and 51 met criteria for review: 24 practice guidelines, 22 studies of screening patterns, and 5 interventions designed to increase BMD rates. Of the practice guidelines, almost one half (47%) lacked a formal description of how they were developed, and recommendations for populations to screen varied widely. Screening frequencies among at-risk patients were low, ranging from 1% to 47%. Only eight studies assessed factors associated with BMD testing. Female patient gender, glucocorticoid dose, and rheumatologist care were positively associated with BMD testing; female physicians, rheumatologists, and physicians caring for more postmenopausal patients were more likely to test patients. Five articles described interventions to increase BMD testing rates, but only two tested for statistical significance and no firm conclusions can be drawn. CONCLUSIONS: This systematic review identified several possible contributors to suboptimal BMD testing rates. Osteoporosis screening guidelines lack uniformity in their development and content. While some patient and physician characteristics were found to be associated with BMD testing, few articles carefully assessed correlates of testing. Almost no interventions to improve BMD testing to screen for osteoporosis have been rigorously evaluated. Key words osteoporosis research methods diagnosis clinical reviews
This work was supported by the Arthritis Foundation and NIH grants K23-AR48616, K24-AR02123, and P60-AR47782.
Marshall D, Joyhnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.
Woodhouse A, Black DM. BMD at various sites for the prediction of hip fracture: a meta-analysis. J Bone Miner Res. 2002;15:S145.
Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72–5.
Centers for Disease Control and Prevention. Healthy People 2010. Available at: http://www.health.gov/healthypeople/, volume1/02Arthritis.htm@_Toc49053811. Accessed April 30, 2004
Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Osteoporosis Prevention, Diagnosis, and Therapy. Rockville, Md: National Institutes of Health; 2000:27.
Solomon DH, Morris CA, Cheng H, et al. A structured review of treatment guidelines, osteoporosis treatment rates, and quality improvement interventions. Under review.
American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:294–312.
Hodgson SF, Johnston CC, Avioli LV, et al. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract. 1996;2:157–71.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496–503.
American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39:1791–801.
Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(suppl 1):1–9.
Compston J. Prevention and treatment of osteoporosis: clinical guidelines and new evidence. J R Coll Physicians Lond. 2000;34:518–21.
Guideline Development Group of the Royal College of Physicians. Osteoporosis: Clinical Guidelines for Prevention and Treatment. London: Royal College of Physicians; 1999.
Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM. 1998;91:71–92.
Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271–92.
National Osteoporosis Society. Guidance on the Prevention and Management of Corticosteroid-induced Osteoporosis. Bath, UK: National Osteoporosis Society; 1998.
Kanis JA, Delmas P, Burckhardt P, et al. The European Foundation for Osteoporosis and Bone Disease, for guidelines for diagnosis and management of osteoporosis. Osteoporos Int. 1997;7:390–406.
Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther. 1999;21:1025–44.
National Osteoporosis Foundation. Osteoporosis: Review of the Evidence for Prevention, Diagnosis, and Treatment and Cost-effectiveness Analysis. Washington, DC: The Foundation; 1998.
National Osteoporosis Foundation. Physician’s Guide to the Prevention and Treatment of Osteoporosis. Available at: http://www.nof.org. Accessed July 18, 2002.
Osteoporosis Clinical Practice Guideline. American Medical Directors Association, Columbia, Md, and American Health Care Association, Washington, DC; 1998.
Sturtridge W, Lentle B, Hanley D. The use of bone density measurement in the diagnosis and management of osteoporosis. CMAJ. 1996;155:924–9.
The prevention and management of osteoporosis: consensus statement. Australian National Consensus Conference 1996. Med J Aust. 1997;167(suppl):S1-S15.
U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. Baltimore, Md: Williams & Wilkins; 1996.
U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526–8.
Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228–51.
Foundation for Osteoporosis Research and Education. Guidelines of Care on Osteoporosis for the Primary Care Physician. Oakland, Calif: Foundation for Osteoporosis Research and Education; 1998.
Sambrook PN, Seeman E, Phillips SR, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust. 2002;176:S1-S16.
Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 suppl):S1-S34.
Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ. 1996;155:1113–29.
Sahota O, Worley A, Hosking DJ. An audit of current clinical practice in the management of osteoporosis in Nottingham. J Public Health Med. 2000;22:466–72.
Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporosis fracture. Arch Intern Med. 2002;162:450–6.
Colon-Emeric C, Yballe L, Sloane R, Pieper CF, Lyles KW. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture. J Am Geriatr Soc. 2000;48:1261–3.
Ridout R, Hawker GA. Use of bone densitometry by Ontario family physicians. Osteoporos Int. 2000;11:393–9.
Solomon CG, Connelly MT, Collins K, Okamura K, Seely EW. Provider characteristics: impact on bone density utilization at a health maintenance organization. Menopause. 2000;7:391–4.
Papa LJ, Weber BE. Physician characteristics associated with the use of bone densitometry. J Gen Intern Med. 1997;12:781–3.
Jaglal SB, McIsaac WJ, Hawker G, Jaakkimainene L, Cadarette SM, Chan BTB. Patterns of use of the bone mineral density test in Ontario, 1992–1998. CMAJ. 2000;163:1139–43.
Harrington JT, Bory SB, DeRosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call for action. Arthritis Care Res. 2002;47:651–4.
Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217–22.
Riley RL, Carnes ML, Gudmundsson A, Elliott ME. Outcomes and secondary prevention strategies for male hip fractures. Ann Pharmacother. 2002;36:17–23.
Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol. 2001;28:2504–8.
Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82-A:1063–70.
Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ. 2000;163:819–22.
Kamel HK, Hussain MS, Tariq S, Perry HM III, Morley JE. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109:326–8.
Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002;61:32–6.
Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis—rates and predictors of care in an academic rheumatology practice. Arthritis Rheum. 2002;46:3136–42.
Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of oteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care. 2001;7:597–605.
Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid-induced osteoporosis prevention in a managed care cohort. J Rheumatol. 2001;28:1298–305.
Smith MD, Cheah SP, Taylor K, Ahern MJ. Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital. J Rheumatol. 2001;28:566–70.
Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med. 2001;161:1322–7.
Osiri M, Saag KG, Ford AM, Moreland LW. Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clin Rheumatol. 2000;6:117–22.
Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL. Prevention of corticosteroid induced osteoporosis: results of a patient survey. Arthritis Rheum. 1999;42:1736–9.
Chevalley T, Hoffmeyer T, Bonjour JP. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporosis Int. 2002;13:450–5.
Wroe A, Salkovskis PM, Rimes KA. The effect of nondirective questioning on women’s decisions whether to undergo bone density screening: an experimental study. Health Psychol. 2000;19:181–91.
Newman ED, Starkey RH, Ayoub WT, et al. Osteoporosis disease management: best practices from the Penn State Geisinger Health System. J Clin Outcomes Manage. 2000;7:23–8.
Pazirandeh M. Does patient partnership in continuing medical education (CME) improve the outcome in osteoporosis management? J Contin Educ Health Prof. 2002;22:142–51.
Stock JL, Waud CE, Corderre JA, et al. Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis. Ann Intern Med. 1998;128:996–9.
Etzioni R, Bery KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991–1998. Urology. 2002;59:251–5.
Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract. 2000;13:1–10.
Anonymous. State-specific cholesterol screening trends—United States, 1991–1999. MMWR Morb Mortal Wkly Rep. 2000;49:750–5.
Moss K, Keen R. Usefulness of bone densitometry in post-menopausal women with clinically diagnosed vertebral fractures (letter). Ann Rheum Dis. 2002;61:667–8.
Nolla JM, Gomez-Vaquero C, Fiter C, et al. Usefulness of bone densitometry in postmenopausal women with clinically diagnosed vertebral fractures. Ann Rheum Dis. 2002;61:73–5.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2004